Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

R348

Other · developed by Rigel Pharmaceuticals

Phase 2 Most advanced trial (none active)
RIGL Developer
2 Registered trials

What is R348?

R348 is an ophthalmic solution tested at several concentrations (0.2%, 0.5%, 1.0%) in single and multiple ascending dose studies, and at 0.2% dosed twice daily. It is studied in keratoconjunctivitis sicca and chronic graft-versus-host disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Immunology, Ophthalmology
Developer
Rigel Pharmaceuticals (RIGL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02040623 Phase 2 Chronic Graft-versus-host Disease Completed RIGL
NCT01733992 Phase 1 Keratoconjunctivitis Sicca Completed RIGL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Graft-versus-host DiseaseKeratoconjunctivitis Sicca

More from Rigel Pharmaceuticals

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RIGL page.

Follow RIGL, the company behind R348

See RIGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RIGL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.